0000000000312509

AUTHOR

Katharina Domschke

showing 13 related works from this author

The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international …

2022

BACKGROUND: . High-quality comprehensive data on short-/long-term physical/mental health effects of the COVID-19 pandemic are needed. METHODS: . The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) is an international, multi-language (n=30) project involving >230 investigators from 49 countries/territories/regions, endorsed by national/international professional associations. COH-FIT is a multi-wave, on-line anonymous, cross-sectional survey [wave 1: 04/2020 until the end of the pandemic, 12 months waves 2/3 starting 6/24 months threreafter] for adults, adolescents (14-17), and children (6-13), utilizing non-probability/snowball and representative samp…

GerontologyDISORDERSTRESSOutcome AssessmentIMPACT[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthRA0421well-beingPandemicHealth careOutcome Assessment Health CareadultsMedicineANXIETYCOVID-19; mental health; functioning; physical health; representative; well-being; resilience; survey; international; psychiatry; depression; anxiety; post-traumatic; COH-FIT; children; adolescents; adultsmental health functioning physical health representative well-being resilience survey international psychiatry depression anxiety post-traumatic COH-FIT children adolescents adultadolescentsChildSCALEPsychiatryeducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyPublic Health Global Health Social Medicine and Epidemiologyadolescents; adults; anxiety; children; COH-FIT; COVID-19; depression; functioning; international; mental health; physical health; post-traumatic; psychiatry; representative; resilience; survey; well-being;psychiatryPsychiatry and Mental healthClinical PsychologyrepresentativeinternationaldepressionProfessional associationLife Sciences & Biomedicinemental healthpost-traumaticPsychopathologyResearch PaperAdultCoronavirus disease 2019 (COVID-19)AdolescentPopulationClinical NeurologyBFfunctioningCOH-FIT; COVID-19; adolescents; adults; anxiety; children; depression; functioning; international; mental health; physical health; post-traumatic; psychiatry; representative; resilience; survey; well-being; Adolescent; Adult; Anxiety; Child; Cross-Sectional Studies; Depression; Humans; Mental Health; Outcome Assessment Health Care; SARS-CoV-2; COVID-19; PandemicschildrenIntervention (counseling)MANAGEMENTHumanssurveyVALIDITYeducationPandemicsresilienceScience & Technologybusiness.industrySARS-CoV-2MORTALITYCOVID-19CAREMental healthHealth CareFolkhälsovetenskap global hälsa socialmedicin och epidemiologiCross-Sectional Studies[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthadolescents; adults; anxiety; children; COH-FIT; COVID-19; depression; functioning; international; mental health; physical health; post-traumatic; psychiatry; representative; resilience; survey; well-being; Adolescent; Adult; Anxiety; Child; Cross-Sectional Studies; Depression; Humans; Mental Health; Outcome Assessment Health Care; SARS-CoV-2; COVID-19; PandemicsCOH-FITNeurosciences & Neurologybusinessphysical health[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Predicting the risk of drug–drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study

2021

ObjectivesThe aim was to use routine data available at a patient’s admission to the hospital to predict polypharmacy and drug–drug interactions (DDI) and to evaluate the prediction performance with regard to its usefulness to support the efficient management of benefits and risks of drug prescriptions.DesignRetrospective, longitudinal study.SettingWe used data from a large multicentred pharmacovigilance project carried out in eight psychiatric hospitals in Hesse, Germany.ParticipantsInpatient episodes consecutively discharged between 1 October 2017 and 30 September 2018 (year 1) or 1 January 2019 and 31 December 2019 (year 2).Outcome measuresThe proportion of rightly classified hospital epi…

DrugHospitals PsychiatricLongitudinal studymedicine.medical_specialtymedia_common.quotation_subjectHealth informaticslaw.invention03 medical and health sciencesPharmacovigilance0302 clinical medicinelawRisk FactorsGermanyPharmacovigilanceMedicineHumans1723Drug Interactions030212 general & internal medicine1506Longitudinal StudiesMedical prescriptionPsychiatryhealth informaticsmedia_commonRetrospective StudiesPolypharmacyClinical pharmacologyReceiver operating characteristicbusiness.industryRGeneral MedicinePharmacology and Therapeuticspsychiatry030227 psychiatryPharmaceutical PreparationsMedicineclinical pharmacologybusinessBMJ Open
researchProduct

Fear Network Unresponsiveness in Women with Anorexia Nervosa

2018

Brain Mappingmedicine.medical_specialtyAnorexia NervosaBrainFearGalvanic Skin ResponseGeneral MedicineAnxietyMagnetic Resonance ImagingEatingPsychiatry and Mental healthClinical PsychologyAnorexia nervosa (differential diagnoses)Neural PathwaysmedicineHumansFemalePsychiatryPsychologyApplied PsychologyPsychotherapy and Psychosomatics
researchProduct

MicroRNA hsa-miR-4717-5p regulates RGS2 and may be a risk factor for anxiety-related traits

2015

Regulator of G-protein Signaling 2 (RGS2) is a key regulator of G-protein-coupled signaling pathways involved in fear and anxiety. Data from rodent models and genetic analysis of anxiety-related traits and disorders in humans suggest down-regulation of RGS2 expression to be a risk factor for anxiety. Here we investigated, whether genetic variation in microRNAs mediating posttranscriptional down-regulation of RGS2 may be a risk factor for anxiety as well. 75 microRNAs predicted to regulate RGS2 were identified by four bioinformatic algorithms and validated experimentally by luciferase reporter gene assays. Specificity was confirmed for six microRNAs (hsa-miR-1271-5p, hsa-miR-22-3p, hsa-miR-3…

AdultMaleCandidate geneSingle-nucleotide polymorphismMIR4717ComorbidityBiologyBioinformaticsPolymorphism Single NucleotideCellular and Molecular NeuroscienceGenes ReporterRisk FactorsmedicineHumansIKBKEGenetic Predisposition to DiseaseAllelepanic disorderLuciferases3' Untranslated RegionsAgoraphobiaAllelesGenetic Association StudiesGenetics (clinical)miRNAGeneticsPanic disorderassociationComputational BiologyReproducibility of Resultsmedicine.diseaseAnxiety DisordersMicroRNAsPsychiatry and Mental healthGene Expression RegulationCase-Control StudiesLinear ModelsAnxiety sensitivityAnxietyFemalemedicine.symptomgene regulationRGS ProteinsAgoraphobiaAmerican Journal of Medical Genetics Part B-neuropsychiatric Genetics
researchProduct

Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry.

2021

PURPOSE The aim of this study was to analyze the epidemiology of polypharmacy in hospital psychiatry. Another aim was to investigate predictors of the number of drugs taken and the associated risks of drug-drug interactions and potentially inappropriate medications in the elderly. METHODS Daily prescription data were obtained from a pharmacovigilance project sponsored by the Innovations Funds of the German Federal Joint Committee. RESULTS The study included 47 071 inpatient hospital cases from eight different study centers. The mean number of different drugs during the entire stay was 6.1 (psychotropic drugs = 2.7; others = 3.4). The mean number of drugs per day was 3.8 (psychotropic drugs …

DrugMalemedicine.medical_specialtyEpidemiologymedia_common.quotation_subjectInappropriate Prescribing030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsPharmacovigilanceEpidemiologyMedicineHumansPharmacology (medical)Drug Interactions030212 general & internal medicineRisk factorPsychiatryPotentially Inappropriate Medication Listmedia_commonAgedPolypharmacyPsychiatrybusiness.industryPharmacoepidemiologyHospitalsPsychotropic drugPharmaceutical PreparationsPolypharmacyFemalebusinessPharmacoepidemiology and drug safetyREFERENCES
researchProduct

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

2021

Introduction The aim of this study was to describe the number and type of drugs used to treat depressive disorders in inpatient psychiatry and to analyse the determinants of potential drug-drug interactions (pDDI) and potentially inappropriate medication (PIM). Methods Our study was part of a larger pharmacovigilance project funded by the German Innovation Funds. It included all inpatients with a main diagnosis in the group of depressive episodes (F32, ICD-10) or recurrent depressive disorders (F33) discharged from eight psychiatric hospitals in Germany between 1 October 2017 and 30 September 2018 or between 1 January and 31 December 2019. Results The study included 14,418 inpatient cases.…

Epidemiologymedicine.medical_treatment0302 clinical medicineRisk FactorsMedicine and Health SciencesAntipsychoticsDrug Interactions030212 general & internal medicineDepression (differential diagnoses)Potentially Inappropriate Medication Listmedia_commonMultidisciplinaryDepressionPharmaceuticsQRDrugsAntidepressantsMiddle AgedAntidepressive AgentsAntidepressant Drug TherapyMedicineAntidepressantDrug Therapy CombinationAntipsychotic AgentsResearch ArticleDrugNeurological Drug Therapymedicine.medical_specialtyPatientsSciencemedia_common.quotation_subject03 medical and health sciencesPharmacotherapyDrug TherapyInternal medicinePharmacovigilanceMental Health and PsychiatrymedicineHumansAntipsychoticProbabilityPolypharmacyPharmacologyInpatientsbusiness.industryMood DisordersOdds ratioHealth CareLogistic ModelsMedical Risk Factorsbusiness030217 neurology & neurosurgeryReceptor Antagonist TherapyPloS one
researchProduct

Subclinical levels of anxiety but not depression are associated with planning performance in a large population-based sample

2017

BackgroundMajor depression and anxiety disorders are known to negatively influence cognitive performance. Moreover, there is evidence for greater cognitive decline in older adults with generalized anxiety disorder. Except for clinical studies, complex executive planning functions and subclinical levels of anxiety have not been examined in a population-based sample with a broad age range.MethodsPlanning performance was assessed using the Tower of London task in a population-based sample of 4240 participants aged 40–80 years from the Gutenberg Health Study (GHS) and related to self-reported anxiety and depression by means of multiple linear regression analysis.ResultsHigher anxiety ratings we…

Male050103 clinical psychologymedicine.medical_specialtyGeneralized anxiety disorderPopulationAnxietyNeuropsychological TestsExecutive Function03 medical and health sciencesCognition0302 clinical medicineGermanyHumansMedicineCognitive Dysfunction0501 psychology and cognitive sciencesProspective StudiesEffects of sleep deprivation on cognitive performanceCognitive declineeducationPsychiatryProblem SolvingApplied PsychologyDepression (differential diagnoses)AgedSubclinical infectioneducation.field_of_studyDepressionbusiness.industry05 social sciencesCognitionMiddle Agedmedicine.disease030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesLinear ModelsAnxietyFemalemedicine.symptombusinessPsychomotor PerformanceClinical psychologyPsychological Medicine
researchProduct

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

2017

AbstractTherapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug…

medicine.medical_specialtyPsychopharmacologyGuidelines as Topic030226 pharmacology & pharmacy03 medical and health sciencesNeuropharmacology0302 clinical medicinePharmacotherapyHealth caremedicineHumansPharmacology (medical)PsychiatryIntensive care medicinePsychotropic Drugsmedicine.diagnostic_testbusiness.industryMental DisordersGeneral Medicinemedicine.disease3. Good healthAntiparkinson drugNeuropsychopharmacologySubstance abusePsychiatry and Mental healthTolerabilityTherapeutic drug monitoringDrug Monitoringbusiness030217 neurology & neurosurgeryPharmacogeneticsPharmacopsychiatry
researchProduct

Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functionin…

2022

BACKGROUND: The COVID-19 pandemic has altered daily routines and family functioning, led to closing schools, and dramatically limited social interactions worldwide. Measuring its impact on mental health of vulnerable children and adolescents is crucial. METHODS: The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT - www.coh-fit.com) is an on-line anonymous survey, available in 30 languages, involving >230 investigators from 49 countries supported by national/international professional associations. COH-FIT has thee waves (until the pandemic is declared over by the WHO, and 6-18 months plus 24-36 months after its end). In addition to adults, COH-FIT also…

GerontologyDISORDER[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthPsychological intervention*Physical healthAdolescentsHVAdolescents; Children; Covid-19; Mental health; Pandemic; Physical health; ResilienceRA0421PandemicCovid-19; Pandemic; Mental health; Physical health; Resilience; Children; AdolescentsMedicineAdolescents; Children; Covid-19; Mental health; Pandemic; Physical health; Resilience; Adolescent; Adult; Child; Cross-Sectional Studies; Health Promotion; Humans; Mental Health; Pandemics; Quality of Life; SARS-CoV-2; COVID-19ChildChildrenSCALEmedia_commonPsychiatry[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology*PandemicPublic Health Global Health Social Medicine and Epidemiology*ResiliencePsychiatry and Mental healthClinical PsychologyProfessional associationMental healthPsychological resilience*Mental healthCovid-19Life Sciences & BiomedicinePsychopathologyCovid-19 Pandemic Mental health Physical health Resilience Children AdolescentsAdultAdolescent*Adolescentsmedia_common.quotation_subjectClinical NeurologyBFPhysical healthHealth PromotionArticle*ChildrenQuality of life (healthcare)Intervention (counseling)HumansVALIDITYPandemicsScience & TechnologyPandemicResiliencebusiness.industrySARS-CoV-2Mental health*Covid-19Folkhälsovetenskap global hälsa socialmedicin och epidemiologiCross-Sectional Studies[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthQuality of LifeNeurosciences & Neurologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Mismatch or allostatic load? Timing of life adversity differentially shapes gray matter volume and anxious temperament

2015

Traditionally, adversity was defined as the accumulation of environmental events (allostatic load). Recently however, a mismatch between the early and the later (adult) environment (mismatch) has been hypothesized to be critical for disease development, a hypothesis that has not yet been tested explicitly in humans. We explored the impact of timing of life adversity (childhood and past year) on anxiety and depression levels (N = 833) and brain morphology (N = 129). Both remote (childhood) and proximal (recent) adversities were differentially mirrored in morphometric changes in areas critically involved in emotional processing (i.e. amygdala/hippocampus, dorsal anterior cingulate cortex, res…

0301 basic medicineMalestressful life eventschildhood maltreatmentEmotionsAnxietySocial EnvironmentDevelopmental psychology0302 clinical medicineGray MatterVBMChildadversitymedia_commonDepressionAdult Survivors of Child AbuseAllostasisBrainGeneral MedicineOrgan SizeMagnetic Resonance ImagingAllostatic loadmedicine.anatomical_structureAllostasisAnxietyFemalemedicine.symptomPsychologymismatchallostatic loadAdultCognitive Neurosciencemedia_common.quotation_subjectExperimental and Cognitive PsychologyAffect (psychology)AmygdalaLife Change Events03 medical and health sciencesYoung AdultmedicineHumansddc:610TemperamentAnterior cingulate cortexBrain morphometryOriginal ArticlesImage Enhancement030104 developmental biologyTemperament030217 neurology & neurosurgerySocial Cognitive and Affective Neuroscience
researchProduct

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder

2018

Psychiatric disorders are thought to have a complex genetic pathology consisting of interplay of common and rare variation. Traditionally, pedigrees are used to shed light on the latter only, while here we discuss the application of polygenic risk scores to also highlight patterns of common genetic risk. We analyze polygenic risk scores for psychiatric disorders in a large pedigree (n ~ 260) in which 30% of family members suffer from major depressive disorder or bipolar disorder. Studying patterns of assortative mating and anticipation, it appears increased polygenic risk is contributed by affected individuals who married into the family, resulting in an increasing genetic risk over generat…

Netherlands Twin Register (NTR)0301 basic medicineMajor Depressive Disorder and Bipolar Disorder Working Groups of the Psychiatric Genomics ConsortiumBipolar DisorderSAMPLEMedicine (miscellaneous)Pedigree chartDisease0302 clinical medicineSCHIZOPHRENIA2.1 Biological and endogenous factorsMedicineAetiologyANTICIPATIONlcsh:QH301-705.5Psychiatry0303 health sciencesDepressionASSOCIATIONSerious Mental IllnessPeer reviewMental HealthSchizophrenia/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingMajor depressive disorderGeneral Agricultural and Biological SciencesEngineering sciences. Technologymedicine.medical_specialtyContext (language use)ArticlePsykiatriGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAGESDG 3 - Good Health and Well-beingddc:570Behavioral and Social Science/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_GeneticsPLINKGenetic TestingBipolar disorderPsychiatryBiology030304 developmental biologybusiness.industryPreventionHuman GenomeAssortative matingmedicine.diseaseBrain Disorders030104 developmental biologyMoodlcsh:Biology (General)Mood disordersAnticipation (genetics)ONSETHuman medicinebusiness030217 neurology & neurosurgery
researchProduct

Neurobiological signature of intimacy in anorexia nervosa

2019

Background Intimacy and psychosexual development represent core problems of anorexia nervosa (AN). Experiential and neurobiological evidence however is scarce. Material and methods Thirty-one female AN patients were compared with 35 non-patients (NP) and 22 recovered participants (REC) by using functional magnetic resonance imaging. Participants viewed pictures of couples in intimate relationships and control stimuli. Results AN patients experienced intimate stimuli with lower valence and dominance. AN showed decreased activation of parietal cortices. NP decreased the prefrontal cortex response, which AN patients did not. REC participants did not differ from NP on a behavioural level, thoug…

AdultSexual BehaviorPICTURE STIMULIDysfunctional familyintimacyanorexia nervosaROMANTIC LOVEArousalACTIVATIONYoung AdultmedicineSEXUALITYHumansValence (psychology)Prefrontal cortexABUSEENVIRONMENTmedicine.diagnostic_testWOMENAROUSALmedicine.diseaseMagnetic Resonance Imagingfunctional magnetic resonance imagingPsychiatry and Mental healthClinical PsychologyEating disordersATTACHMENT REPRESENTATIONAnorexia nervosa (differential diagnoses)Psychosexual developmentFemaleFunctional magnetic resonance imagingPsychologyFEMALESClinical psychologyEuropean Eating Disorders Review
researchProduct

GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathw…

2017

Contains fulltext : 177350.pdf (Publisher’s version ) (Closed access) The molecular genetics of panic disorder (PD) with and without agoraphobia (AG) are still largely unknown and progress is hampered by small sample sizes. We therefore performed a genome-wide association study with a dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia Cognition Questionnaire (ACQ) in a sample of 1370 healthy German volunteers of the CRC TRR58 MEGA study wave 1. A genome-wide significant association was found between ACQ and single non-coding nucleotide variants of the GLRB gene (rs78726293, P=3.3 x 10-8; rs191260602, P=3.9 x 10-8). We followed up on this finding in a larger dimensional AC…

0301 basic medicineMaleStartle responseReflex StartleQH301 BiologyGenome-wide association studyGene mutationAnxiety0302 clinical medicineCognitionReceptors GlycineGene FrequencyGermanyGWASHyperekplexiaGeneticsPanic disordermedicine.diagnostic_testStartleBrainFearGLRBAnxiety DisordersPsychiatry and Mental healthSchizophreniaUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Panic DisorderFemalemedicine.symptomPsychologyBDCRC0321 Neuroscience. Biological psychiatry. NeuropsychiatryClinical psychologyAdultGenotypeNDASQH426 Genetics03 medical and health sciencesCellular and Molecular NeuroscienceQH301Fear networkSpastic mousemedicineHumansGenetic Predisposition to DiseaseMolecular BiologyQH426AgoraphobiaAllelesNeurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]Panic disorderOther Research Radboud Institute for Health Sciences [Radboudumc 0]medicine.diseaseStartle reaction030104 developmental biologyMCPCase-Control StudiesMutationRC0321030217 neurology & neurosurgeryAgoraphobiaGenome-Wide Association StudyMolecular psychiatry
researchProduct